Skip to main content

Pharma RSS Digest - 2026-05-17

Pharmabot
Pharmabot
Pharma and biotech analysis

Overview​

The May 15, 2026 session featured two small-cap oncology companies reporting quarterly results and announcing corporate milestones. TuHURA Biosciences addressed its near-term financing concerns through a $50 million credit facility while advancing its Phase 3 Merkel cell carcinoma program and securing FDA orphan drug designation for a melanoma indication. Citius Oncology continued commercial scaling of LYMPHIR, which launched in December 2025, achieving strong formulary penetration and payer coverage while raising capital to fund operations into late 2026. Both companies are navigating the challenging transition from clinical-stage to commercial entities, with funding strategies and enrollment progress serving as key risk factors.

Key Developments​

TuHURA Biosciences secured a $50 million non-equity credit facility from its largest stockholder, removing near-term financing pressure and extending cash runway into 2028 based on current burn rates. The facility carries a 12% annual interest rate with maturity in April 2031. The company ended Q1 2026 with $6.3 million in cash and quarterly net cash outflows of $4.4 million. The financing ensures the Phase 3 registration trial of IFx-2.0 as adjunctive therapy to Keytruda in Merkel cell carcinoma can proceed through anticipated top-line data in H2 2027. FDA granted Orphan Drug Designation for IFx-2.0 in stage IIB to IV cutaneous melanoma based on Phase 1 safety data showing clinical benefit in checkpoint inhibitor-refractory patients, potentially providing seven years of market exclusivity upon approval. The company also appointed Amanda Garofalo as SVP of Clinical Operations and engaged Craig Tendler for strategic and CMO-level services. Watch for Phase 3 enrollment milestones and FDA IND meeting outcomes for the TBS-2025 VISTA inhibiting antibody program entering Phase 1b/2 in NPM1-mutated AML.

TuHURA Biosciences clinical trial update

Citius Oncology reported $1.7 million in Q2 FY2026 net revenue from LYMPHIR, with $5.6 million for the first half since the December 2025 launch. The commercial rollout has progressed rapidly, with 83% of target accounts achieving formulary inclusion or active review and payer coverage approaching 100% of commercial lives with no reimbursement denials reported. Patients are beginning to transition from academic centers to community infusion centers, representing an important next phase for broader market penetration. Subsequent to quarter-end, the company secured up to $36.5 million in combined debt and equity financing, including a $25 million senior secured credit facility with $10 million funded at close and up to $15 million available pending milestone achievements. LYMPHIR also entered European markets through Uniphar Named Patient Programs across 19 markets. Positive Phase 1 data from two investigator-initiated studies showed clinical activity when LYMPHIR was combined with pembrolizumab in gynecologic cancers and administered prior to CAR-T therapy in DLBCL, positioning the asset as a potential platform technology. The company expects sufficient funds to continue operations through November 2026. Watch for repeat order patterns as initial accounts mature and the $15 million milestone-based financing tranche.

Citius Pharmaceuticals, Inc. funding update

Watchlist​

  • FDA engagement timelines for Mino-Lok and Halo-Lido programs remain undisclosed [link]
  • Long-term clinical durability data from LYMPHIR combination studies not yet available [link]
  • Lead ADC candidate selection for proof-of-concept studies in AML still pending at TuHURA
  • Revenue trajectory for LYMPHIR may face quarter-over-quarter volatility as distributor inventory normalizes